Biotech comes to its 'antisenses' after hard-won drug approval

Nature

Biotech comes to its 'antisenses' after hard-won drug approval"


Play all audios:

Loading...

Access through your institution Buy or subscribe “With any brand new technology, you never know when the world will be ready for it.” So said Paul Boni, an analyst at Punk, Ziegel &


Knoll, in 1998 (as quoted by the _New York Times_), after the US Food and Drug Administration (FDA) approved its first gene-silencing 'antisense therapy', a drug known as Vitravene


(fomivirsen), for the treatment of cytomegalovirus infections in individuals with weakened immune systems. The arrival of Vitravene, a short strand of 21 DNA molecular units that blocks


viral replication, was hailed as a major milestone for the biotech industry and was widely anticipated to usher in a new era of antisense products. But no more came. And by the middle of the


last decade, Isis Pharmaceuticals, the Carlsbad, California–based company behind Vitravene, ended up pulling the therapy from the market because improvements in other antiretrovirals had


effectively eliminated the drug's target market. Boni's cautionary words proved all too prescient. This is a preview of subscription content, access via your institution RELEVANT


ARTICLES Open Access articles citing this article. * DNA/RNA HETERODUPLEX OLIGONUCLEOTIDE FOR HIGHLY EFFICIENT GENE SILENCING * Kazutaka Nishina * , Wenying Piao *  … Takanori Yokota _Nature


Communications_ Open Access 10 August 2015 * MERKEL CELL CARCINOMA: EPIDEMIOLOGY, TARGET, AND THERAPY * Mathew P. Hughes * , Matthew E. Hardee *  … Ling Gao _Current Dermatology Reports_


Open Access 22 January 2014 ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn


more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS


OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support Authors * Kevin Jiang View author publications You can also search for this author


inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Jiang, K. Biotech comes to its 'antisenses' after hard-won drug


approval. _Nat Med_ 19, 252 (2013). https://doi.org/10.1038/nm0313-252 Download citation * Published: 06 March 2013 * Issue Date: March 2013 * DOI: https://doi.org/10.1038/nm0313-252 SHARE


THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to


clipboard Provided by the Springer Nature SharedIt content-sharing initiative


Trending News

Saffron may treat post COVID-19 symptoms, suggest Kashmiri scientists

A team of scientists in Kashmir has suggested that saffron — the world’s costliest spice — can be used as a treatment fo...

Chatburn court, warrington road, warrington, wa3 5rb:man/00eu/ldc/2020/0058

CHATBURN COURT, WARRINGTON ROAD, WARRINGTON, WA3 5RB:MAN/00EU/LDC/2020/0058 Northern Region Judge K Southby and Member M...

Truckers Told to Avoid Violence in Port Strike

A union of truck drivers was ordered Thursday to refrain from acts of violence on one of several picket lines at contain...

Car damaged in vijayawada floods? From repairs to insurance, all you need to know

In general, there are two types of damages that your car may sustain if the floods have harmed it: engine damage and acc...

Has The NFL’s Instant Replay Run Its Course? | FiveThirtyEight

There’s a classic coachspeak phrase that gets trotted out when people blame losses on bad officiating: “You’ve got to ta...

Latests News

Biotech comes to its 'antisenses' after hard-won drug approval

Access through your institution Buy or subscribe “With any brand new technology, you never know when the world will be r...

National Nielsen Viewership - Los Angeles Times

Here are the rankings for national prime-time network television last week (Aug. 27-Sept. 2) as compiled by Nielsen Medi...

Has The NFL’s Instant Replay Run Its Course? | FiveThirtyEight

There’s a classic coachspeak phrase that gets trotted out when people blame losses on bad officiating: “You’ve got to ta...

Car damaged in vijayawada floods? From repairs to insurance, all you need to know

In general, there are two types of damages that your car may sustain if the floods have harmed it: engine damage and acc...

Truckers Told to Avoid Violence in Port Strike

A union of truck drivers was ordered Thursday to refrain from acts of violence on one of several picket lines at contain...

Top